Pepfamin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pepfamin

Here is a quick overview of the medicine Pepfamin at the identity level.

Property Description
Active Ingredient Famotidine (C₈H₁₅N₇O₂S₃)
Form Oral Tablet, Oral Suspension, Intravenous (IV) Solution
Pharmacological Class Histamine H₂-receptor Antagonist (H₂-blocker)
Common Use Acid Suppressant, Antiulcer Agent
Origin Synthetic Small Molecule

What Type of Medicine is Pepfamin and What is its Composition?

Pepfamin is a specific pharmaceutical preparation whose medicinal function is provided by its active ingredient, Famotidine. This medication is definitively classified as a Histamine H₂-receptor antagonist (or H₂-blocker), a designation rooted in its specific mechanism of action. Famotidine belongs to a class of medications that work by decreasing the amount of acid made in the stomach. Famotidine is a single-ingredient product, and as a synthetic small molecule, it possesses the chemical formula C₈H₁₅N₇O₂S₃.

Pepfamin is available in various dosage forms, most notably the oral tablet for administration by the oral route, though preparations like oral suspension and specialized intravenous solution (IV) are also manufactured to accommodate different patient needs, particularly in hospital settings.


What is the General Purpose of Pepfamin?

The general purpose of Pepfamin is to act as an acid suppressant and an antiulcer agent, strategically managing problems related to excessive acid in the digestive tract. Famotidine is used to inhibit gastric acid secretion. Therefore, the medicine's core function is to proactively reduce the amount and strength of gastric secretion, a property clinically recognized for its ability to provide sustained relief. By performing this targeted function as an H₂-blocker, Pepfamin helps to relieve the common burning and irritation associated with high stomach acidity, such as heartburn or acid indigestion.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Pepfamin?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Pepfamin (Famotidine) based on government regulatory labeling. The information is categorized by frequency and the body systems affected, in line with standardized regulatory reporting.


Frequency-Classified Adverse Reactions

Classification Examples of Documented Reactions
Common (ge 1/100 to < 1/10) Headache, Dizziness, Constipation, Diarrhea
Uncommon (ge 1/1000 to < 1/100) Dry mouth, Nausea, Vomiting, Rash, Fatigue
Rare/Very Rare Agranulocytosis, Anaphylaxis, Stevens-Johnson Syndrome, AV block
Not Known Seizures, Confusion, Hepatitis, QT interval prolongation

System-Organ Classes and Serious Reactions

Adverse effects are documented across various System-Organ Classes, including the Gastrointestinal, Nervous, Immune, Hepatobiliary, and Blood and Lymphatic Systems.

Regulatory labeling identifies certain events as Serious Adverse Reactions, which include severe hypersensitivity (e.g., Anaphylaxis), severe dermatological reactions, and rare Blood Dyscrasias. The occurrence of QT interval prolongation and Atrioventricular (AV) block is primarily noted with intravenous use, especially in patients with impaired renal function.


Population-Specific Safety Considerations

Patients with renal impairment are documented to have an increased risk of central nervous system and cardiac adverse effects. Additionally, before initiating treatment for gastric ulcer, regulatory documents mandate that the possibility of underlying gastric malignancy must be excluded, as symptomatic improvement with Famotidine does not rule out the presence of cancer.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents state that the adverse reactions encountered in cases of overdose with Pepfamin (Famotidine) are generally similar to those experienced during routine clinical use.

Documented Overdose Manifestations and Risks

Element Official Regulatory Statement
Documented Manifestations Symptoms may include agitation, confusion, hallucinations, drowsiness, slurred speech, nausea, diarrhea, low blood pressure, and an abnormal heartbeat (rapid or slow).
Severe Outcomes Life-threatening events noted are seizures (convulsions), arrhythmias, QT prolongation, and becoming unawakable (collapse).
Vulnerable Populations Patients with impaired renal function and elderly patients are at an increased risk of severe Central Nervous System (CNS) adverse reactions.
Antidote Status No specific antidote is known; management involves symptomatic and supportive treatment.

When to Seek Urgent Medical Help

Regulatory authorities mandate that you seek immediate medical help or contact a Poison Control Center right away in case of suspected overdose. Emergency services must be called immediately if the affected person has collapsed, had a seizure, has trouble breathing, or can’t be awakened. Supportive measures may include ECG monitoring and intravenous fluids as necessary.

Therapeutic Uses of Pepfamin

Addressing Burning Sensations and Acid Pain

This medication is commonly used in situations involving certain distressing symptoms, primarily the burning pain of heartburn and the discomfort of acid regurgitation, which are symptoms related to physical discomfort in the upper digestive tract. It is applied across domains where additional symptomatic support is needed in conditions related to excessive stomach acid. This includes managing symptoms of recurrent Gastroesophageal Reflux Disease (GERD) and easing discomfort associated with gastric and duodenal ulcers.

This medication is applied in addressing symptom clusters that may become intense or disruptive. It provides support that helps ease the overall symptom load and supports general well-being during symptomatic phases. It is often used during phases when symptoms become more noticeable and interfere with daily functioning, such as those that disrupt sleep and mealtimes.

“It is relevant for easing symptoms associated with recurrent and episodic manifestations.”

It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations, thereby assisting with maintaining functional stability during symptomatic periods.


Quick Fact: Use in managing Heartburn and Ulcer Discomfort This medication is commonly used to help manage symptoms linked to organ-specific functional stress caused by excess acid.

Eligibility and Restrictions for Use

Population Eligibility and Restrictions for Pepfamin

Pepfamin (Famotidine) is subject to specific population eligibility rules defined by government regulatory agencies. The medicine is contraindicated and must not be used by patients with a history of hypersensitivity to famotidine or any other medicine in the Histamine H₂-receptor antagonist class.

Restrictions by Patient Group

Category Regulatory Status (Official Labeling)
Adult Use Approved for use across all labeled indications.
Pediatric Use Approved for oral tablet use in patients mathbf40 kg or more; safety is not established for intravenous use in children less than one year of age.
Renal Impairment Use is restricted in patients with moderate or severe renal impairment (creatinine clearance less than 60 mL/min).
Pregnancy Not recommended for use unless deemed clearly necessary.
Lactation Not recommended; mothers should either discontinue the medicine or discontinue breastfeeding.

Additionally, official documents mandate a pre-treatment restriction: in patients with gastric ulcer symptoms, the possibility of gastric malignancy must be excluded before Pepfamin is initiated.

What should I know about interactions with other medicines?

Pepfamin (Famotidine) is an H2-receptor antagonist that works by reducing the amount of acid produced in the stomach. This action can affect the absorption of certain other medications that require a specific level of stomach acid to be properly absorbed into the bloodstream. It is essential to consult a healthcare provider or pharmacist regarding all current medications and supplements, including over-the-counter drugs and herbal products, to prevent potential interactions.

Medications with Altered Absorption

Pepfamin may decrease the effectiveness of certain drugs by reducing their absorption. This is particularly relevant for drugs that are weak bases and depend on a low stomach pH for dissolution. Such medications include:

  • Antifungals: Such as ketoconazole and itraconazole.
  • Certain HIV/AIDS medications: Including atazanavir and rilpivirine.
  • Select Cancer Drugs: Including dasatinib and erlotinib.

Other Significant Interactions

Concomitant use with other medications may lead to increased side effects due to altered metabolism or clearance:

Interacting Drug Class/Example Potential Outcome
Tizanidine (muscle relaxant) Increased tizanidine levels, raising the risk of side effects like sleepiness or low blood pressure.
Warfarin (blood thinner) Potentially increased effects of warfarin, which could increase the risk of bleeding.

Products to Discuss with a Healthcare Provider

Other acid-reducing agents, such as other H2-blockers or Proton Pump Inhibitors (PPIs), should generally not be taken concurrently with Pepfamin. While no significant food interactions are known, alcohol consumption may worsen gastrointestinal symptoms, which is a consideration for patients treating ulcers or reflux.

Mechanism of Action

How Pepfamin Works

Pepfamin (Famotidine) acts through a specific pharmacodynamic mechanism that modulates gastric acidity at the cellular level. The drug does not neutralize existing acid but prevents its formation by interrupting a key biological cascade.


Targeting the Histamine mathbfH2-Receptor

The foundational action of Pepfamin is its function as a competitive antagonist at the Histamine mathbfH2-receptor, which is a key activator of acid production located on the parietal cells of the stomach lining. By binding to this receptor, Pepfamin prevents the natural signaling molecule, histamine, from activating the cell, thereby disrupting a major stimulus for secretion.


Interrupting the Intracellular Signaling Cascade

The blockade of the H2-receptor immediately stops a subsequent G-protein-mediated signaling cascade that involves the second messenger cyclic AMP (cAMP). This interruption diminishes the cell's secretory machinery, leading to a reduction in the activation of the final acid-secreting enzyme, the Proton Pump ( H^+/ K^+-ATPase). This mechanism results in a measurable and sustained reduction in the volume and acidity of the fluid released into the stomach lumen.


Mechanism Limitations and Specificity

This mechanism operates with a high degree of specificity for the histamine pathway and is consequently less influential on acid secretion strongly stimulated by other secretagogues like acetylcholine or gastrin. Furthermore, the activity of the H2 receptor blockade can sometimes diminish with prolonged, continuous exposure, a phenomenon known as tachyphylaxis or tolerance.

Dosage and Administration Information

How Pepfamin is Used in Clinical Practice

Pepfamin (Famotidine) is an acid suppressant whose administration is dictated by official prescribing information regarding route, dose, frequency, and duration. The medicine is available for both oral administration (tablet or suspension) and intravenous (IV) administration (solution). Oral forms may be taken with or without food.


Standard Dosing and Administration Schedules

Official dosing is tailored to the condition, defining standardized regimens for acute treatment and long-term maintenance:

Indication Standard Adult Oral Dosing Frequency/Timing
Acute Ulcer 40 mg or 20 mg 40 mg once daily at bedtime or 20 mg twice daily
Ulcer Maintenance 20 mg Once daily at bedtime
Hypersecretory Conditions Starting at 20 mg Every 6 hours, adjusted based on response

IV administration is reserved strictly for short-term use in patients unable to take oral medication; it is administered as a slow injection over at least two minutes or an infusion over 15 to 30 minutes. For the oral suspension, the medicine must be shaken vigorously before measuring the dose.


Population-Specific Use

Official instructions require dose adjustments for patients with renal impairment (creatinine clearance less than 60 mL/min). This modification typically involves a reduction in dose or an extension of the dosing interval (e.g., every 36 to 48 hours) to prevent accumulation. Conversely, the dosage regimen for older adults is generally the same as for younger adults, as age alone does not mandate adjustment. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pepfamin

Evidence for Ulcer Healing and Prevention

Research examined the use of Pepfamin for conditions characterized by active duodenal and gastric ulcers in short-term, randomized, controlled trials (RCTs). These studies were applied in research contexts involving patients with endoscopically confirmed ulcers, monitoring the endoscopic ulcer healing rate and patient-reported outcomes describing perceived discomfort. The research included adults and some specific pediatric populations.

The findings described patterns observed in the studies where the observed proportion of healed ulcers in the treated populations differed from the proportions noted in the control groups. These trials also examined differences in the time until patients reported changes in physical discomfort between the study groups. Research also examined patterns related to the recurrence of duodenal ulcers over observation intervals lasting up to twelve months.


Research on GERD and Symptom Modulation

Pepfamin was studied for its relevance in trials assessing short-term or episodic symptom patterns linked to Gastroesophageal Reflux Disease (GERD) and episodic heartburn symptoms. Outcomes measured included the healing status of erosive lesions and patient-reported outcomes describing discomfort and the frequency of acid regurgitation. Studies monitored populations during the acute phases of GERD, reporting how symptoms evolved, with differences in the proportion of patients reporting changes in symptoms noted between the study groups compared to controls.

Evidence derived from research settings provides limited insight into outcomes of using the medication daily over extended periods for chronic heartburn conditions outside of a formal GERD diagnosis. The data are still emerging regarding the sustained outcomes for patients continuing therapy beyond the acute 12-week treatment period for erosive lesions.


Key Uncertainties and Research Gaps

Research has not fully characterized the long-term effects of Pepfamin use for chronic symptom management extending beyond one year; follow-up durations were limited in primary maintenance trials. For both pediatric patients and older adults, while research describes observed patterns, sample sizes were limited in some studies, and data for these specific groups remain insufficient to draw conclusions about long-term use. For rare conditions, such as the pathological hypersecretory states, the evidence quality varies across studies, with research relying more on open-label studies where comparative evidence is lacking.

Frequently Asked Questions (FAQ)

Common questions about Pepfamin (FAQ)


Q: How quickly should I expect to feel a difference after starting Pepfamin?

A: Official product information indicates that the acid-reducing effect of Pepfamin generally begins within one hour after being taken by mouth. The maximum acid suppression is usually reached within one to three hours, with the overall effect on stomach acid production typically lasting between 10 to 12 hours.

Q: Can Pepfamin be taken at the same time as standard pain relievers?

A: Regulatory documents suggest that Pepfamin does not significantly interfere with the action of most common pain relievers. However, since the medicine is sometimes combined with nonsteroidal anti-inflammatory drugs (NSAIDs) in certain products, information regarding the use of Pepfamin alongside any specific pain reliever should be reviewed with a pharmacist or healthcare provider.

Q: Is it safe to use Pepfamin if I have a history of mild kidney issues?

A: Because Pepfamin is primarily cleared from the body by the kidneys, patients with severe kidney problems may require a lower dose or less frequent dosing. Caution is generally advised for individuals with kidney disease. Use of the medicine should be managed by a healthcare professional.

Q: Why do some people say Pepfamin causes tiredness, is this a known side effect?

A: Official labeling documents confirm that fatigue is an uncommon adverse reaction associated with Pepfamin. Side effects related to the nervous system, such as unusual drowsiness or somnolence, have also been reported. Persistent or severe tiredness should be reported to a healthcare provider.

Q: If I miss a dose of Pepfamin, what's the recommended catch-up procedure?

A: Official instructions for a missed dose advise that it may be taken as soon as remembered. However, if it is nearly time for the next scheduled dose, the missed dose is usually skipped. A double dose should not be taken to make up for a forgotten one.

Q: How long can a person safely stay on a course of Pepfamin?

A: For over-the-counter (OTC) use, the medicine should typically not be used for more than 14 days unless the course is determined by a healthcare professional. For chronic conditions treated under prescription, the treatment length is determined by the healthcare provider based on the specific condition.

Q: Is Pepfamin suitable for use in elderly patients?

A: Generally, the recommended dosing regimen for older adults is the same as for younger adults, as age alone does not require adjustment. However, official information notes that older adults are more likely to have reduced kidney function, which may necessitate a reduction in dose or a less frequent dosing schedule.

Q: Is it normal to experience a slightly upset stomach when first taking Pepfamin?

A: Gastrointestinal side effects such as constipation, diarrhea, nausea, vomiting, or dry mouth are known and documented in regulatory sources. Constipation and diarrhea are listed as common side effects. If symptoms are severe or persist, consulting with a healthcare provider is recommended.

Q: Can Pepfamin affect the results of routine lab tests?

A: Regulatory reports document that adverse reactions have occurred across various body systems, including the Blood and Lymphatic Systems and the Hepatobiliary System. This means that changes in certain lab values, such as liver enzymes or blood cell counts, may be detected, though these occurrences are generally rare.

Q: Does Pepfamin have any known psychological or mood-related side effects?

A: Rare or very rare psychiatric adverse reactions have been reported in official documents, including confusion, disorientation, agitation, anxiety, and depression. These are reported more often in individuals with underlying kidney problems or in older adults.

Q: Does alcohol consumption significantly impact how Pepfamin works?

A: Official drug interactions information does not suggest that alcohol changes the way Pepfamin itself works in the body. However, consuming alcohol may intensify or worsen the underlying gastrointestinal symptoms, such as those related to ulcers or reflux, that the medicine is being used to treat.

Q: Can women who are planning pregnancy use Pepfamin?

A: Official regulatory information states that the drug is not generally recommended for use during pregnancy unless clearly necessary. Because specific data on use during the 'planning' phase is limited, consultation with a healthcare provider is necessary when planning to become pregnant while taking this medicine.

Q: How long does Pepfamin stay active in the body after the last dose?

A: The elimination half-life of Pepfamin (the time it takes for half of the drug to be cleared) is approximately 2.5 to 3.5 hours for people with normal kidney function. The acid-suppressing effect is clinically observed to last for about 10 to 12 hours after a single dose.

Q: Does Pepfamin have any known interactions with common over-the-counter cold medicines?

A: While the official label does not specifically list interactions with common cold medicines, it is important to be cautious. Some cold products may contain ingredients that should not be taken with Pepfamin, such as other acid reducers. It is necessary to consult with a healthcare professional or pharmacist regarding all over-the-counter medicines being taken.

Q: Is there a generic version of Pepfamin available?

A: Yes, the active ingredient in Pepfamin, which is Famotidine, is available as a generic drug. Generic versions are listed and approved in governmental databases under Abbreviated New Drug Applications.

Q: Can I crush or split the Pepfamin tablet if I have trouble swallowing pills?

A: The labeling for the standard oral tablet does not include instructions allowing it to be crushed or split. For patients who have difficulty swallowing tablets, other forms, such as an oral suspension or orally disintegrating tablets, may be available and may require discussion with a pharmacist.

Q: Are there any dietary restrictions specifically mentioned when taking Pepfamin?

A: Official instructions state that Pepfamin tablets can be taken with or without food. Aside from the general caution about alcohol potentially worsening symptoms, no other specific dietary restrictions are mentioned in the regulatory drug label.

Q: What level of evidence exists for the benefits of Pepfamin?

A: Official regulatory bodies have approved Pepfamin for its labeled uses, such as ulcer healing and managing GERD symptoms, based on findings from controlled studies. These studies include randomized, controlled trials (RCTs), which provide strong evidence supporting its effectiveness in these indications.

Q: How often do serious side effects from Pepfamin actually occur?

A: Serious side effects, such as severe allergic reactions (anaphylaxis) or rare blood disorders, are classified as 'Rare' or 'Very Rare' in regulatory documents. This classification generally indicates they occur in less than 1 in 1,000 patients who take the medicine.

Q: Is the effectiveness of Pepfamin influenced by the time of day it's taken?

A: Yes, timing can be important. For certain conditions, such as ulcer maintenance, the official dosing schedule recommends taking the once-daily dose at bedtime. This specific timing helps to suppress the production of acid during the night, which is crucial for promoting healing.

Q: What should I do if I suspect an allergy to Pepfamin?

A: Regulatory documents include a clear Allergy Alert, warning against using the drug if there is an allergy to Famotidine or other acid reducers. If signs of a severe allergic reaction, such as difficulty breathing, swelling, or hives, appear, immediate emergency medical attention should be sought.

Q: Does Pepfamin affect blood pressure or heart rate?

A: Oral use of Pepfamin generally has not been associated with systemic effects on the heart rate or blood pressure. However, serious cardiac events, including heart rhythm disturbances, have been noted, primarily with intravenous administration and typically only in individuals who have pre-existing kidney impairment.

Q: Can I drive or operate heavy machinery while taking Pepfamin?

A: Because Pepfamin can cause side effects like dizziness, headache, or confusion, which may impair alertness, caution is advised. Caution is also advised for driving or operating heavy machinery until the effect of the medicine is known.

How should Pepfamin be stored and disposed of?

How to Store and Dispose of Pepfamin?

The storage conditions for Pepfamin (Famotidine) are defined by the regulatory drug label to ensure stability and safety.

Famotidine Oral Tablets must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The tablets must be kept in a well-closed, light-resistant container and protected from excessive moisture. Famotidine IV Solution requires strict refrigerated storage between 2 C and 8 C (36 F to 46 F).

All forms of the medication must be stored out of the reach and sight of children.

Regarding disposal, unused or expired product must be discarded according to local regulations for pharmaceutical waste. Medicine should generally not be flushed down the toilet unless explicitly authorized by the official drug label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pepfamin found in:

A-Z Index: